Company intelligence / Profile preview

Micron Biotech

Atlanta, Georgia, United States

Ownership: Private
Development stage: Other

Overview

Next-generation needle-free patch vaccines for measles/rubella achieved positive Phase 1 safety/immunogenicity in children as young as 9 months. Rotavirus vaccine currently in human trials (with Emory and CDC). mRNA flu vaccine, Disease X vaccine patches, and long-acting contraceptive are in preclinical/early-stage clinical development.

Therapeutic areas: Infectious DiseasesWomen's Health
Modalities: Microbial therapymRNA-based drugsVaccineSmall moleculeBiologic
Industry: Biotech

Partnerships

Emory UniversityCDC (Centers for Disease Control)Zipcode BioCEPI (Coalition for Epidemic Preparedness Innovations)BARDA (Biomedical Advanced Research and Development Authority)Bill & Melinda Gates Foundation

Beyond the preview

Go deeper on Micron Biotech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Micron Biotech.

Explore the full profile